EU Moves Closer to Kicking Kids off Social Media

Instagram, TikTok, Snapchat, Kick, YouTube, Facebook, Twitch, Reddit, Threads and X applications are displayed on a mobile phone in this picture illustration taken on December 9, 2025. (Reuters)
Instagram, TikTok, Snapchat, Kick, YouTube, Facebook, Twitch, Reddit, Threads and X applications are displayed on a mobile phone in this picture illustration taken on December 9, 2025. (Reuters)
TT

EU Moves Closer to Kicking Kids off Social Media

Instagram, TikTok, Snapchat, Kick, YouTube, Facebook, Twitch, Reddit, Threads and X applications are displayed on a mobile phone in this picture illustration taken on December 9, 2025. (Reuters)
Instagram, TikTok, Snapchat, Kick, YouTube, Facebook, Twitch, Reddit, Threads and X applications are displayed on a mobile phone in this picture illustration taken on December 9, 2025. (Reuters)

Restrictions on children's use of social media in the European Union could come as early as this summer, as a long-awaited expert report next week is expected to recommend limiting minors' access to online platforms.

After Australia became the first country in the world to ban under-16s from social media, several EU nations including Denmark and Greece demanded a similar move.

The EU says all options are on the table, from a blanket ban on children from social media platforms to restrictions on certain services and features.

It appears there is little appetite for a broadbrush approach and EU officials insist no decisions have been taken before the panel tasked by EU chief Ursula von der Leyen delivers its recommendations on July 13.

Von der Leyen has indicated in the past she supports restrictions, with a formal announcement expected in September -- although that could change.

"It is not the question when children or teenagers would have access to social media, I would say it's more the question when social media has access to our children and teenagers," she said last week.

She is under pressure as some European capitals including Paris have already drawn up their own legislation, although Brussels on Monday told France to amend its draft law since it encroached on the European Commission's powers.

The EU says it will do more to protect children online -- not just on social media.

"Whatever decisions are made on age limits, we must also tackle the business models and design choices shaping children's online experiences every day," EU consumer protection commissioner Michael McGrath told AFP.

Risk-based limits?

The panel is not expected to recommend a blanket social media ban either.

For an idea on what to expect, observers point to a German panel that put forward two options last month: a statutory minimum age of 13 -- which many platforms have -- or restrictions on individual services and features.

The European Commission, the EU's digital watchdog, has been closely watching how the ban unfolded in Australia -- where there have been challenges -- and could opt for a different approach.

Brussels could take a risk-based approach, prohibiting features it views as harmful rather than banning platforms like Instagram, Snapchat or TikTok.

Bans have been growing in popularity worldwide, with Britain and Indonesia taking similar steps. Many EU states like Greece and Spain have also prepared their own bans, though Estonia fiercely opposes such a move.

A majority of Europeans surveyed in France, Germany, Italy, Poland, and Spain, for a YouGov poll published on Thursday want platforms to remove "harmful" design features like endless scroll and personalized content feeds.

Digital rights experts say bans are not the right way to go, arguing the EU should instead make platforms safer for children with the legal armory it has.

"We don't think that exclusion is the answer. We need to enforce our existing laws," Simeon de Brouwer of digital rights group EDRi told AFP, adding he hoped new strengthened consumer protection rules would be "ambitious".

McGrath said the new law expected later this year would "recognize children as vulnerable consumers" and that minors "must be protected by design".

'Responsibility lies with platforms'

Such steps are backed by Europeans.

The YouGov poll found 75 percent of the over 5,100 adults surveyed said platforms should be inaccessible to minors until they can prove they are safe.

"We must focus on measures that ensure the responsibility lies with the platforms to prove their products are safe before they can be used by children, or anyone," Michiel van Hulten, EU director at Reset Tech, said.

The EU has a significant legal weapon in the form of an online content law that forces the world's biggest platforms to ensure harmful and dangerous content is swiftly removed and bans targeted advertisements to children.

But de Brouwer said the EU was "timid" about enforcing the law. While the EU told Chinese-owned TikTok to change its "addictive design", it has only told US-based Meta to enforce age verification, he said.

An EU official told AFP, however, the commission is set to issue findings against Meta's Facebook and Instagram in a probe looking at how their services may cause addictive behavior in children before the summer ends.



‘Gus’ the T. Rex Fetches Record $50.1 Mn at US Auction

This undated photo provided by Sotheby's on Tuesday, July 14, 2026, shows "Gus," one of the largest and most complete Tyrannosaurus rex specimens ever discovered. (Matthew Sherman/Sotheby's via AP)
This undated photo provided by Sotheby's on Tuesday, July 14, 2026, shows "Gus," one of the largest and most complete Tyrannosaurus rex specimens ever discovered. (Matthew Sherman/Sotheby's via AP)
TT

‘Gus’ the T. Rex Fetches Record $50.1 Mn at US Auction

This undated photo provided by Sotheby's on Tuesday, July 14, 2026, shows "Gus," one of the largest and most complete Tyrannosaurus rex specimens ever discovered. (Matthew Sherman/Sotheby's via AP)
This undated photo provided by Sotheby's on Tuesday, July 14, 2026, shows "Gus," one of the largest and most complete Tyrannosaurus rex specimens ever discovered. (Matthew Sherman/Sotheby's via AP)

A Tyrannosaurus rex skeleton nicknamed "Gus" sold Tuesday for $50.1 million at Sotheby's in New York, making it the most valuable dinosaur fossil bought at auction after a 10-minute battle between seven bidders.

"Gus" is one of the world's most complete T. rex skeletons -- with 183 fossilized bones -- and was discovered on a cattle ranch in South Dakota in 2021.

The giant beast lived some 72 to 66 million years ago -- a period characterized by a warm climate, high sea levels and vast floodable coastal plains.

The skeleton measures 38 feet (11.6 meters) in body length, making it one of the largest T. rexes ever discovered. It is roughly 63 percent complete.

Tuesday's purchase by an anonymous buyer highlights a surging market for dinosaur bones -- a trend that has drawn criticism from some paleontologists over the specimens going into private hands.

"The United States is the only country in the world where fossils like this are considered personal property," Cassandra Hatton, head of science and natural history at Sotheby's, told AFP before the auction.

"If you own the land, you own the fossil and you have the right to sell it. So if you want a dinosaur, this is the only place that you can get it," she said.

The previous record for a fossil auction was "Apex" the Stegosaurus, bought for $44.6 million in 2024 by hedge fund billionaire Ken Griffin.


An Experimental Alzheimer’s Drug Shows Promise Targeting a Different Brain Protein, New Study Shows

 These brain scan images provided by Biogen show how high levels of Alzheimer's-related tau protein, in red, dropped in a recipient of the company's experimental drug diranersen. (Biogen via AP)
These brain scan images provided by Biogen show how high levels of Alzheimer's-related tau protein, in red, dropped in a recipient of the company's experimental drug diranersen. (Biogen via AP)
TT

An Experimental Alzheimer’s Drug Shows Promise Targeting a Different Brain Protein, New Study Shows

 These brain scan images provided by Biogen show how high levels of Alzheimer's-related tau protein, in red, dropped in a recipient of the company's experimental drug diranersen. (Biogen via AP)
These brain scan images provided by Biogen show how high levels of Alzheimer's-related tau protein, in red, dropped in a recipient of the company's experimental drug diranersen. (Biogen via AP)

An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called tau, researchers reported Tuesday.

Tau is one part of a toxic duo fueling Alzheimer’s but prior attempts to develop drugs that can target the protein have failed. Two Alzheimer’s drugs, lecanemab and donanemab, try to clear buildup of the better-known amyloid protein and can modestly slow cognitive decline.

The new findings suggest Biogen's diranersen did more than lower tau levels. The study of about 400 people found signs that it also slowed cognitive decline, in one small subset enough to be comparable to amyloid therapy, according to results presented at the Alzheimer's Association International Conference in London. Biogen is planning a larger study to try to prove the drug’s benefit.

“This is really quite promising if it were to hold up” in that next-step testing, said Jessica Langbaum of the Banner Alzheimer’s Institute in Phoenix, who wasn’t involved with Biogen’s study.

“This is early days,” cautioned Dr. Reisa Sperling of Mass General Brigham, who also wasn’t involved in the study. But “I think it will reinvigorate interest and investment in lots of tau mechanisms, and the field needs that.”

It’s one of multiple novel attempts to fight the mind-destroying disease, including a possible tau vaccine, an experimental heart drug that might do double-duty for some people at high risk of Alzheimer's, and ways to help medicines more easily get across the so-called blood-brain barrier.

It’s not clear exactly what causes Alzheimer’s, which affects more than 7 million Americans and tens of millions worldwide. That sticky amyloid protein starts building up to form plaques in the brain about two decades before symptoms appear. But amyloid alone isn’t enough to cause Alzheimer's.

Many scientists believe that amyloid buildup eventually triggers an abnormal form of tau to form tangles in neurons, setting off symptoms.

Diranersen is what’s called an antisense oligonucleotide that doesn't attack tau buildup but instead instructs a tau-producing gene to produce less.

“If you lower tau production, you are lowering the amount of the abnormal tau that needs to be cleared by the microglia, by the clearance mechanism in the brain. And so, you are enabling the normal clearance mechanism to have more capacity to clear the tau,” said Dr. Cath Mummery of University College London, who led the new study.

Today’s anti-amyloid drugs are given through the bloodstream via infusions or injections. Diranersen is injected into the fluid surrounding the spinal cord, a straighter path to the brain.

Biogen's tau drug missed a key study goal — but was still encouraging Biogen’s study included people with mild cognitive impairment or mild Alzheimer’s, randomly assigning them to different doses of diranersen or a placebo.

Back in May, Biogen and partner Ionis Pharmaceuticals announced that the lowest dose — given every six months — had the strongest effect. That was a counterintuitive surprise and meant the study didn't meet its planned goal of showing that higher doses brought greater benefits.

Still, scientists had been anxiously awaiting details about how much that twice-a-year spinal shot really helped. Five of six different brain tests showed diranersen recipients’ memory and other cognitive abilities still worsened but more slowly than those given dummy shots, Mummery said.

In one test of the lowest dose, that translated to a 26% reduction in cognitive decline — “approximately the same” change seen in earlier tests of amyloid drugs, she said.

Side effects included injection site pain and a temporary state of confusion that could appear a few days after the shot and last about a week, she said. But there were no signs of brain inflammation, which can affect recipients of anti-amyloid drugs.

Alzheimer's researchers also target tau in a broad new study

The University of California, San Francisco, last week opened a first-of-its-kind study known as the Alzheimer’s Tau Platform.

Funded by the National Institutes of Health, it will test a variety of experimental anti-tau therapies against and in combination with today’s amyloid treatments. First up is a vaccine called AADvac1 designed to train the immune system to recognize and fight a specific worrisome portion of the tau protein, said UCSF's Dr. Adam Boxer.

The “platform” approach will expand to locations around the country, allow addition of other tau drugs to test and include people with Alzheimer’s-related protein buildup who aren’t yet showing symptoms, he said.

Other studies hint at new ways of attacking Alzheimer's

Researchers told the Alzheimer’s meeting that an experimental cholesterol-lowering drug called obicetrapib might do more than help heart health. They're exploring if it also might lower buildup of Alzheimer's-related proteins in people who carry a genetic risk for the disease.

Why? That gene, called APOE4, also affects how the body processes cholesterol. Obicetrapib maker NewAmsterdam Pharma plans to begin a study soon to test if the drug's cholesterol effects also can mitigate the Alzheimer's risk in people carrying one or two copies of that gene.

Companies also are trying to get Alzheimer’s drugs into the brain faster and at higher volumes, by penetrating the protective lining meant to protect the brain from harm.

Denali Therapeutics' CEO Ryan Watts describes it as “hitching a ride” with iron that naturally gets into the brain. His company is pursuing drugs that target tau and amyloid using that “transport vehicle” technology.


A US-Russian Space Crew Launches on a Mission to the International Space Station

The Soyuz rocket is rolled out by train to the launch pad, Saturday, July 11, 2026, at Site 31 of the Baikonur Cosmodrome in Kazakhstan. (Bill Ingalls/NASA via AP)
The Soyuz rocket is rolled out by train to the launch pad, Saturday, July 11, 2026, at Site 31 of the Baikonur Cosmodrome in Kazakhstan. (Bill Ingalls/NASA via AP)
TT

A US-Russian Space Crew Launches on a Mission to the International Space Station

The Soyuz rocket is rolled out by train to the launch pad, Saturday, July 11, 2026, at Site 31 of the Baikonur Cosmodrome in Kazakhstan. (Bill Ingalls/NASA via AP)
The Soyuz rocket is rolled out by train to the launch pad, Saturday, July 11, 2026, at Site 31 of the Baikonur Cosmodrome in Kazakhstan. (Bill Ingalls/NASA via AP)

A US-Russian space crew blasted off successfully Tuesday on a mission to the International Space Station.

NASA astronaut Anil Menon and Russian crewmates Pyotr Dubrov and Anna Kikina lifted off from the Russia-leased Baikonur cosmodrome in Kazakhstan aboard the Roscosmos Soyuz MS-29 for an eight-month stint on the orbiting outpost. They are set to dock at the station three hours after the launch, The AP news reported.

Isaacman ’s trip to the Russia-leased Baikonur cosmodrome in Kazakhstan marked the first visit by a NASA chief in eight years.

Speaking during Monday’s meeting with the crew, Isaacman thanked Russia's state space corporation, Roscosmos, for its efforts to prepare for the mission, saying that “the integrated work performed over the past several months reflects the professionalism and dedication of everyone involved.”

Isaacman also met with Roscosmos head Dmitry Bakanov before the launch of NASA astronaut Anil Menon and Russian crewmates Pyotr Dubrov and Anna Kikina. They were set to blast off aboard the Roscosmos Soyuz MS-29 for an eight-month stint on the International Space Station.

The mission is Menon’s first space flight and the second for Dubrov and Kikina.

The trio will join NASA astronauts Jessica Meir, Jack Hathaway and Chris Williams, European Space Agency astronaut Sophie Adenot and Roscosmos cosmonauts Sergei Kud-Sverchkov, Sergei Mikaev and Andrei Fedyaev.

Once bitter rivals in the space race during the Cold War, Russia and the US cooperate on the space station and other projects. That relationship was marred by tensions after Moscow sent troops into Ukraine in 2022, but Washington and Moscow have continued to work together, with US and Russian crews flying to the orbiting outpost on each country’s spacecraft.

Plans for broader cooperation, including possible Russian involvement in NASA’s Artemis program of lunar research, have fallen apart. As Russia has become increasingly reliant on China for its energy exports and imports of key technology amid Western sanctions, Roscosmos has started cooperation with China on its prospective lunar mission.